

## **Product datasheet for TL319299**

## OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US

Rockville, MD 20850, US
Phone: +1-888-267-4436
https://www.origene.com
techsupport@origene.com
EU: info-de@origene.com
CN: techsupport@origene.cn

## **GPIHBP1 Human shRNA Plasmid Kit (Locus ID 338328)**

**Product data:** 

**Product Type:** shRNA Plasmids

**Product Name:** GPIHBP1 Human shRNA Plasmid Kit (Locus ID 338328)

**Locus ID:** 338328

**Synonyms:** GPI-HBP1; HYPL1D

Vector: pGFP-C-shLenti (TR30023)

E. coli Selection: Chloramphenicol (34 ug/ml)

Mammalian Cell

Selection:

Puromycin

Format: Lentiviral plasmids

Components: GPIHBP1 - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID =

338328). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.

RefSeq: NM 001301772, NM 178172, NM 178172.1, NM 178172.2, NM 178172.3, NM 178172.4,

NM 178172.5, NM 001301772.1, BC035810, BC063857, NM 001301772.2

UniProt ID: O8IV16

Summary: This gene encodes a capillary endothelial cell protein that facilitates the lipolytic processing of

triglyceride-rich lipoproteins. The encoded protein is a glycosylphosphatidylinositol-anchored protein that is a member of the lymphocyte antigen 6 (Ly6) family. This protein plays a major role in transporting lipoprotein lipase (LPL) from the subendothelial spaces to the capillary lumen. Mutations in this gene are the cause of hyperlipoproteinemia, type 1D. Alternate

splicing results in multiple transcript variants. [provided by RefSeq, Sep 2014]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





## Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).